Tim Bullock
Co-Founder @ New Wave Ventures
London, United Kingdom
Tim Bullock is a seed investor at New Wave Ventures in London focused on FinTech and Finance. Tim Bullock spent 26 years in banking and finance. Following 6 years in specialist business finance with Barclays, he moved to NatWest where he established Lombard Bank as a leading innovator in marketing and processing techniques. During 14 years as a Managing Director with Lloyds, he led his business through a period of rapid growth to become themost profitable in its sector.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Tim Bullock invests in
Stages Tim Bullock invests in
Countries Tim Bullock invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- FinTech 2 (33%)
- Finance 2 (33%)
- Internet 2 (33%)
- Financial Services 2 (33%)
- Banking 1 (17%)
Stage
- Seed 2 (33%)
- Series A 1 (17%)
- Series B 1 (17%)
- Funding Round 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Endomag is a medical technology company devoted to improving the global standard of cancer care. The company's Sentimag probe, Magseed marker, and Magtrac node marker are already in use by many of the world’s leading physicians and cancer centers. Endomag's goal is to help women with breast cancer avoid surgery when it isn’t needed, andexperience better outcomes when it is. As of 2019, the company has already helped 70,000+ women around the world access more precise and less invasive breast cancer care.Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag continues to develop its unique clinical platform from its headquarters in Cambridge, United Kingdom. The company sells its products through a network of distributors in Europe, the Middle East, Africa, and Australasia. | $2.6M / Series B / Nov 20, 2014 | ||
| Endomag is a medical technology company devoted to improving the global standard of cancer care. The company's Sentimag probe, Magseed marker, and Magtrac node marker are already in use by many of the world’s leading physicians and cancer centers. Endomag's goal is to help women with breast cancer avoid surgery when it isn’t needed, andexperience better outcomes when it is. As of 2019, the company has already helped 70,000+ women around the world access more precise and less invasive breast cancer care.Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag continues to develop its unique clinical platform from its headquarters in Cambridge, United Kingdom. The company sells its products through a network of distributors in Europe, the Middle East, Africa, and Australasia. | $2.8M / Series B / Aug 13, 2013 | ||
| The ID Co., builds products based on (open) bank data that help businesses onboard their customers quickly.DirectID, their business service, helps businesses like lenders to create exceptional customer experiences by removing friction caused during the application process by the current challenges of risk, compliance, fraud, and regulation.Theproducts They provide solve business pains such as assessing customers' affordability and verifying their account information, thereby offsetting credit risk.The platform currently connects to 5,500 banks in 30 countries and will soon support Open Banking in the UK. They presently have more than 30 customers on the platform and have just launched with Clydesdale, a leading UK retail bank, to provide bank data as part of their mobile app experience.The business is authorised by the FCA to provide AISP (Account Information Service Provider) services to the UK market. | $2.5M / Seed / Apr 30, 2012 | ||
| Atto takes the lead with a clear mission, to shape a more predictable future for lenders. Using real-time bank transaction data, Atto delivers a suite of predictive models to empower risk management.Atto offers a range of insights that gives risk managers a detailed view of customer spending, saving, and earning. This added level of understandingenhances credit risk assessment and promotes a more compliant lending environment.Providing accurate foresight lies at the heart of Atto's values. By leveraging current financial information, consumers are more likely to receive equitable treatment, whilst businesses gain the tools to make more informed and appropriate lending decisions.With innovation in data science at its core, Atto paves the way for a future where complex decisions can be made in real-time with impossibly recent data. | $2.5M / Seed / Apr 30, 2012 | ||
| Endomag is a medical technology company devoted to improving the global standard of cancer care. The company's Sentimag probe, Magseed marker, and Magtrac node marker are already in use by many of the world’s leading physicians and cancer centers. Endomag's goal is to help women with breast cancer avoid surgery when it isn’t needed, andexperience better outcomes when it is. As of 2019, the company has already helped 70,000+ women around the world access more precise and less invasive breast cancer care.Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag continues to develop its unique clinical platform from its headquarters in Cambridge, United Kingdom. The company sells its products through a network of distributors in Europe, the Middle East, Africa, and Australasia. | $786K / Series A / Nov 11, 2011 | ||
| Aeristech as an engineering R&D consultancy firm to develop Hybrid Turbo Technology. | Sep 27, 2010 |
Co-Investors
About New Wave Ventures
New Wave Ventures is a privately owned fund seeking the opportunity to invest for the long term in companies with significant growth potential. Their target initial investment is £500,000 to £2,000,000. They invest their own money without the need for external investors or borrowings. They are not driven by the need to service interest charges orto dispose of their investments by an artificial deadline. They do not believe in using leverage to boost their returns. They are willing to co-invest with like-minded investors, although their preference is to be the sole investor alongside owner-managers.
New Wave Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ian George
Chief Scientific Officer
|
|||
Clare Twemlow
Chief Financial Officer
|
|||
Paul Newey
Co-Founder
|
|||
|
Tim Bullock
Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Tim Bullock invest in?
Tim Bullock invests primarily in FinTech, Finance and Internet startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tim Bullock?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Tim Bullock last invest?
The most recent investment recorded for Tim Bullock closed in Nov 2014. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
